Clinical Trial: 5HT3 Antagonism and Auditory Gating in Schizophrenia


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

5HT3 Antagonism and Auditory Gating in Schizophrenia

This study is currently recruiting patients.

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs

Purpose

The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Another purpose of this study is to determine how the altered brain functioning in schizophrenia contributes the symptoms found in the illness.

Condition	Treatment or Intervention
Schizophrenia	Drug: ondansetron Behavior: neuropsychological testing Drug: nicotine Drug: haloperidol

MedlinePlus related topics: Schizophrenia

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacokinetics Study

Further Study Details:

Study start: June 1998; Study completion: June 2003

Eligibility

Ages Eligible for Study: 18 Years - 55 Years, Genders Eligible for Study: Both

Criteria

Subjects with diagnosed with schizophrenia will be studied.

Location and Contact Information

Colorado
VAMC, Denver, Colorado, 80013, United States; Recruiting

Ellen Cawthra, RN 303-315-7023 ellen.Cawthra@uchsc.edu
Lawrence E. Adler, Principal Investigator

More Information

Study ID Numbers: MHBS-013-99F
Record last reviewed: June 2001
Record first received: July 3, 2001
ClinicalTrials.gov Identifier: NCT00018850
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-10-22

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services